<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039684</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-2021-44</org_study_id>
    <nct_id>NCT05039684</nct_id>
  </id_info>
  <brief_title>Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical Prostaglandins</brief_title>
  <official_title>Inflammatory Biomarkers in Ocular Surface in Patients With Primary Open Angle Glaucoma and Ocular Hypertension Under Topical Prostaglandin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a chronic optic neuropathy whose main modifiable risk factor is an abnormally&#xD;
      elevated intraocular pressure. The aim of glaucoma treatment is to slow the progression of&#xD;
      the disease by reducing intraocular pressure.&#xD;
&#xD;
      Prostaglandin derivatives are the most effective topical drugs in reducing intraocular&#xD;
      pressure (IOP). Among these, latanoprost was the first agent of this type to be approved for&#xD;
      use in patients with glaucoma or ocular hypertension.&#xD;
&#xD;
      These eye drops are available with and without preservatives. There are two commercial brands&#xD;
      in our environment, Xalatan®, which contains 0.005% latanoprost and 0.2 mg/ml benzalkonium&#xD;
      chloride (BAK) and Monoprost®, which contains the same amount of latanoprost but does not&#xD;
      carry a preservative. The prostaglandin analog with a lower concentration of active&#xD;
      ingredient available in Spain without preservative is tafluprost 0.0015%, commercially&#xD;
      available under the name Saflutan®.&#xD;
&#xD;
      The long-term use of hypotensive eye drops with preservatives generates changes in the ocular&#xD;
      surface, such as instability of the tear film, conjunctival inflammation, subconjunctival&#xD;
      fibrosis, apoptosis of the conjunctival epithelium and deterioration of the corneal surface,&#xD;
      causing symptoms such as stinging, tearing, sensation foreign body, photophobia and blurred&#xD;
      vision.&#xD;
&#xD;
      This research will evaluate the changes in the ocular surface and in the expression of&#xD;
      inflammatory molecules that occur in the conjunctiva in patients with a diagnosis of glaucoma&#xD;
      and ocular hypertension who are under ocular hypotensive treatment with tafluprost, comparing&#xD;
      it with the two commercial preparations of latanoprost.&#xD;
&#xD;
      These three groups of patients will have a control group of patients with a diagnosis of&#xD;
      ocular hypertension who will not have any topical hypotensive medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory response in ocular surface secondary to prostaglandin use</measure>
    <time_frame>24 hours</time_frame>
    <description>Presence of inflammatory cytokines in ocular surface</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival cell phenotype and inflammatory infiltration</measure>
    <time_frame>24 hours</time_frame>
    <description>Conjunctival cell phenotype assessment by conjunctival in vivo confocal microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in oxidative stress in the tear film</measure>
    <time_frame>24 hours</time_frame>
    <description>Changes in oxidative stress at conjunctiva secondary to prostaglandin treatment</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Primary open angle glaucoma / ocular hypertension - Treatment with Xalatan</arm_group_label>
    <description>Patients with primary open angle glaucoma or ocular hypertension treated with Xalatan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary open angle glaucoma / ocular hypertension - Treatment with Monoprost</arm_group_label>
    <description>Patients with primary open angle glaucoma or ocular hypertension treated with Monoprost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary open angle glaucoma / ocular hypertension - Treatment with Saflutan</arm_group_label>
    <description>Patients with primary open angle glaucoma or ocular hypertension treated with Saflutan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ocular hypertension - No treatment</arm_group_label>
    <description>Patients ocular hypertension untreated</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      A 1-2 microL tear sample. Conjunctival impression cytology&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with ocular hypertension or primary open angle glaucoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary open angle glaucoma or ocular hypertension as defined in Early&#xD;
             Manifest Glaucoma Trial&#xD;
&#xD;
          -  &gt; 18 years old&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  3 or more months under monotherapy treatment with tafluprost 0.0015%, latanoprost&#xD;
             0.005% with BAK 0.2mg/ml or latanoprost 0.005%.&#xD;
&#xD;
          -  Untreated patients with ocular hypertension must be treatment naïve for the pathology.&#xD;
&#xD;
          -  No presence or history of previous ocular diseases other than glaucoma or ocular&#xD;
             hypertension, started before the use of hypotensive medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular surgery in the previous 6 months.&#xD;
&#xD;
          -  Any ocular surface disease not related to inclusion criteria or related issues active&#xD;
             within the last 6 months.&#xD;
&#xD;
          -  Any topical treatment other than the evaluated in this study in the last 3 months.&#xD;
&#xD;
          -  In case of artificial teardrops use, only non conservative ones are allowed, with no&#xD;
             more than 4 times per day use, and treatment must be suspended 5 days before&#xD;
             inclusion.&#xD;
&#xD;
          -  Use of contact lenses in the las 4 weeks.&#xD;
&#xD;
          -  Any mental or physical disease that may prevent performing the required tests for the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carolina Ossa Calderon, MD</last_name>
    <phone>983184734</phone>
    <email>cossac@ioba.med.uva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Blazquez Arauzo, MD, MsC</last_name>
    <phone>983184734</phone>
    <email>blazquez@ioba.med.uva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IOBA</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Carolina Ossa Calderon, MD, MsC</last_name>
      <phone>983184734</phone>
      <email>cossac@ioba.med.uva.es</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Blazquez Arauzo, MD, MsC</last_name>
      <phone>983184734</phone>
      <email>blazquez@ioba.med.uva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Carolina Ossa Calderon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ramon Juberias Sanchez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Calonge Cano, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yolanda Diebold Luque, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>prostaglandin</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>biomarker</keyword>
  <keyword>inflammation</keyword>
  <keyword>confocal in-vivo microscopy</keyword>
  <keyword>cornea</keyword>
  <keyword>tear film</keyword>
  <keyword>conjunctiva</keyword>
  <keyword>impression cytology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

